Suven secures Japanese patents for two Alzheimer drugs

The Japanese Patent Office (JPO) has granted Suven Life Sciences Ltd two patents on its new chemical entities for the treatment of central nervous system (CNS) disorders.

The product patents - `4455992' and `4473120' - on the NCEs meant for the treatment of disorders associated with neurodegenerative diseases, are valid until 2022, Suven Life Sciences said in a release.

With this Suven has secured a total of three product patents from the Japanese Patent Office.

Suven said the class of selective Serotonin receptor affinity compounds discovered by the company and are being developed as therapeutic agents.

The compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, according to the patent disclosure.

Suven said it has a number of product patent applications from its `Discovery Research' are in the pipeline and has secured intellectual property protection for several of their NCEs in major markets like the US, Canada, Europe, China, Russia, India, Japan, Australia, New Zealand, Brazil and Mexico.